Living unrelated donors in kidney transplants: Better long-term results than with non-HLA-identical living related donors?

Transplantation

Volumn 69, Issue 9, 2000, Pages 1942-1945

  Humar, Abhinav ^a   Durand, Brenda ^a   Gillingham, Kristen ^a   Payne, William D ^a   Sutherland, David E ^a   Matas, Arthur J ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; LYMPHOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; CADAVER; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECIPIENT; RISK BENEFIT ANALYSIS; SURVIVAL RATE;

EID: 0034657870     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200005150-00033     Document Type: Article

References (18)

1. Penn I, Halgrimson CG, Ogden F, Starzl TE. Use of living donors in kidney transplantation in man. Arch Surg 1970; 101: 226.
2. Cecka JM. The UNOS scientific renal transplant registry. In: Cecka JM, Terasaki PI, eds. Clinical transplants 1998. Los Angeles: UCLA Tissue Typing Laboratory, 1998: 1.
3. Sutherland DER. Living related donors should be used whenever possible. Transplant Proc 1985; 27: 1503.
4. Pirsch JD, Sollinger HW, Kalayoglu M, et al. Living-unrelated renal transplantation: results in 40 patients. Am J Kidney Dis 1988; 12: 499.
5. Park K, Kim YS, Lee EM, Lee HY, Han DS. Single-center experience of unrelated living-donor renal transplantation in the cyclosporine era. Clin Transplant 1992; 23: 249.
6. D'Alessandro AM, Pirsch JD, Knechtl SJ, et al. Living unrelated renal donation: The University of Wisconsin experience. Surgery 1998; 124: 604.
7. Almond PS, Matas A, Gillingham K, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55: 752.
8. Perez RV, Matas AJ, Gillingham KJ, et al. Lessons learned and future hopes: three thousand renal transplants at the University of Minnesota. In: Terasaki PI, ed. Clinical transplants 1990. Los Angeles: UCLA Tissue Typing Laboratory, 1991: 217.
9. Diethelm AG, Deierhoi MH, Hudson SL, et al. Progress in renal transplantation: a single center study of 3359 patients over 25 years. Ann Surg 1995; 221: 446.
10. D'Alessandro AM, Sollinger HW, Knechtl SJ, et al. Living related and unrelated donors for kidney transplantation: a 28-year experience. Ann Surg 1995; 222: 353.
11. Jones JW, Gillingham KJ, Sutherland DER. Successful long-term outcome with O-haplotype-matched living related kidney donors. Transplantation 1994; 57: 512.
12. Bertolatus JA. Renal transplantation for the nephrologist: living donor kidney transplantation - what did we learn during the 1980s? What should we learn during the 1990s? Am J Kidney Dis 1991; 27: 596.
13. Massy ZA, Guijarro C, Wiederkehr MR, Ma JZ, Kasiske BL. Chronic renal allograft rejection: immunologic and nonimmunologic risk factors. Kidney Int 1996; 49: 518.
14. Terasaki PI, Koyama H, Ceck JM, Gjertson DW. The hyperfiltration hypothesis in human renal transplantation. Transplantation 1994; 57: 1450.
15. Matas AJ. Risk factors for chronic rejection: a clinical perspective. Transplant Immunol 1998; 6: 1.
16. Dunn DL, Mayoral JL, Gillingham KJ, et al. Treatment of invasive CMV disease in solid organ transplant patients with ganciclovir. Transplantation 1991; 51: 98.
17. Humar A, Uknis M, Carlone-Jambor C, Gruessner RW, Dunn DL, Matas A. Cytomegalovirus disease recurrence after ganciclovir treatment in kidney and kidney-pancreas transplant recipients. Transplantation 1999; 67: 94.
18. DeGeest S, Borgermans L, Gemoets H, et al. Incidence, determinants, and consequences of subclinical noncompliance with immunosuppressive therapy in renal transplant recipients. Transplantation 1995; 59: 340.